Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?

On June 3, European regulators gave a green light to bluebird bio's (NASDAQ: BLUE) beta-thalassemia therapy, Zynteglo, and on Friday, management revealed plans to charge $1.8 million for the revolutionary new treatment. Its million-plus price sounds exorbitant, but it may not be as ridiculous as it seems. Here's how Zynteglo may transform the treatment of this genetic disorder.